6.8M views · 6.6K reactions | What are the SARS-CoV-2 variants circulating at this time? How are variants classified as variants of interest or concern? What does this mean for the public? WHO’s COVID-19 Technical Lead Dr Maria Van Kerkhove explains in this Science in 5 video. | World Health Organization Western Pacific Region | Facebook

Dr Maria Van Kerkhove, WHO's technical lead on COVID-19, talks about the status of the scientific work needed to find the origins of the SARS-CoV-2 virus. 👉Why it is important to understand the origins of pandemics, 👉What is WHO's role in achieving this and, 👉How WHO works to prevent future pandemics. | World Health Organization (WHO)

SARS-CoV-2 infection produces detectable immune responses; however, the extent to which previously infected people are protected from a second infection is uncertain. Understanding whether post-infection immunity exists and how long it lasts has major implications for the SARS-CoV-2 pandemic. New research findings are summarized in a short video. https://nej.md/3q0frZL | The New England Journal of Medicine

60K views · 1.8K reactions | HONORING A VACCINE SCIENTIST: "The View" praises a scientist who’s an expert on the front lines of the global race for a SARS-CoV-2 vaccine, Dr. Kizzmekia Corbett. Learn how she’s making history developing the science that could end the pandemic. abcn.ws/3j56ZWu | The View | Facebook

The mRNA-1273 SARS-CoV-2 vaccine had high short-term efficacy, but its medium-term efficacy and safety are not known. https://nej.md/2YfXzla | The New England Journal of Medicine

Preliminary data indicated high efficacy of an mRNA-based vaccine developed in collaboration between Moderna and the NIAID. The vaccine has now been evaluated in an ongoing phase 3 randomized, controlled trial. New research findings are summarized in a short video. https://nej.md/3tstdX9 | The New England Journal of Medicine